1. Home
  2. CAPT vs MBAI Comparison

CAPT vs MBAI Comparison

Compare CAPT & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAPT

Captivision Inc.

N/A

Current Price

$0.42

Market Cap

13.2M

Sector

Finance

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.73

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPT
MBAI
Founded
2005
2004
Country
South Korea
Israel
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
10.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CAPT
MBAI
Price
$0.42
$1.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
152.1K
50.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$1.31
52 Week High
$1.93
$3.92

Technical Indicators

Market Signals
Indicator
CAPT
MBAI
Relative Strength Index (RSI) 43.83 50.28
Support Level $0.40 $1.38
Resistance Level $0.46 $1.89
Average True Range (ATR) 0.02 0.15
MACD 0.00 0.00
Stochastic Oscillator 43.40 56.60

Price Performance

Historical Comparison
CAPT
MBAI

About CAPT Captivision Inc.

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: